 Kimi Kondo
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology | 4 | 2017 | 140 | 0.690 |
Why?
| | Lymphocele | 1 | 2013 | 2 | 0.440 |
Why?
| | Curriculum | 4 | 2018 | 825 | 0.420 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 62 | 0.410 |
Why?
| | Faculty | 1 | 2013 | 130 | 0.390 |
Why?
| | Kidney Neoplasms | 4 | 2016 | 333 | 0.300 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 487 | 0.300 |
Why?
| | Kidney Transplantation | 1 | 2013 | 541 | 0.290 |
Why?
| | Clinical Competence | 1 | 2013 | 896 | 0.270 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 977 | 0.260 |
Why?
| | Ultrasonography, Interventional | 2 | 2016 | 123 | 0.240 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2016 | 36 | 0.230 |
Why?
| | Angiomyolipoma | 2 | 2016 | 17 | 0.230 |
Why?
| | Internship and Residency | 1 | 2013 | 932 | 0.220 |
Why?
| | Diagnostic Imaging | 2 | 2016 | 275 | 0.210 |
Why?
| | Students, Medical | 2 | 2017 | 262 | 0.190 |
Why?
| | Education, Medical, Undergraduate | 2 | 2018 | 159 | 0.160 |
Why?
| | Radiology, Interventional | 1 | 2018 | 26 | 0.160 |
Why?
| | Schools, Medical | 2 | 2018 | 120 | 0.140 |
Why?
| | Vena Cava Filters | 1 | 2017 | 50 | 0.140 |
Why?
| | Thromboembolism | 1 | 2017 | 93 | 0.140 |
Why?
| | Pregnancy, Abdominal | 1 | 2016 | 2 | 0.140 |
Why?
| | Teaching | 1 | 2018 | 214 | 0.130 |
Why?
| | Radiology Information Systems | 1 | 2016 | 25 | 0.130 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 36 | 0.130 |
Why?
| | Biotechnology | 1 | 2016 | 41 | 0.130 |
Why?
| | Laboratories | 1 | 2017 | 95 | 0.130 |
Why?
| | Prosthesis Design | 1 | 2017 | 285 | 0.130 |
Why?
| | Venous Thrombosis | 1 | 2017 | 140 | 0.130 |
Why?
| | Cavernous Sinus | 1 | 2015 | 14 | 0.130 |
Why?
| | Organizational Innovation | 1 | 2016 | 133 | 0.130 |
Why?
| | Hypertension, Portal | 1 | 2016 | 61 | 0.130 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 181 | 0.120 |
Why?
| | Portal Vein | 1 | 2016 | 76 | 0.120 |
Why?
| | Venous Insufficiency | 1 | 2015 | 11 | 0.120 |
Why?
| | Personal Satisfaction | 1 | 2017 | 182 | 0.120 |
Why?
| | Radiography, Interventional | 1 | 2016 | 104 | 0.120 |
Why?
| | Methotrexate | 1 | 2016 | 227 | 0.120 |
Why?
| | Arteriovenous Fistula | 1 | 2015 | 29 | 0.120 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2015 | 51 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 370 | 0.120 |
Why?
| | Radiology Department, Hospital | 1 | 2014 | 15 | 0.110 |
Why?
| | Hernia, Abdominal | 1 | 2013 | 6 | 0.110 |
Why?
| | Ascites | 1 | 2013 | 33 | 0.110 |
Why?
| | Hernia, Inguinal | 1 | 2013 | 27 | 0.110 |
Why?
| | Intestinal Obstruction | 1 | 2013 | 40 | 0.110 |
Why?
| | Embolization, Therapeutic | 1 | 2015 | 177 | 0.110 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2013 | 45 | 0.110 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 38 | 0.110 |
Why?
| | Treatment Outcome | 6 | 2016 | 9089 | 0.100 |
Why?
| | Translocation, Genetic | 1 | 2012 | 94 | 0.100 |
Why?
| | Education, Medical | 1 | 2014 | 216 | 0.090 |
Why?
| | Disease Progression | 3 | 2013 | 2384 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 811 | 0.090 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 95 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2012 | 642 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 227 | 0.080 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 52 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 833 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 73 | 0.080 |
Why?
| | Liver Neoplasms | 1 | 2013 | 507 | 0.080 |
Why?
| | Neuroblastoma | 1 | 2010 | 132 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 311 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 364 | 0.080 |
Why?
| | Pyridines | 1 | 2012 | 425 | 0.080 |
Why?
| | Pyrimidines | 1 | 2011 | 378 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2199 | 0.080 |
Why?
| | DNA Methylation | 1 | 2011 | 496 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2009 | 196 | 0.070 |
Why?
| | United States | 4 | 2018 | 12176 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 795 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4622 | 0.060 |
Why?
| | Aged | 5 | 2016 | 19079 | 0.060 |
Why?
| | Anatomic Landmarks | 2 | 2016 | 23 | 0.060 |
Why?
| | Humans | 15 | 2018 | 114716 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 973 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2269 | 0.050 |
Why?
| | Young Adult | 4 | 2016 | 10462 | 0.040 |
Why?
| | Male | 6 | 2016 | 55558 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2312 | 0.040 |
Why?
| | Female | 8 | 2016 | 59486 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2011 | 1176 | 0.040 |
Why?
| | Intergenerational Relations | 1 | 2017 | 15 | 0.040 |
Why?
| | Forecasting | 1 | 2018 | 331 | 0.030 |
Why?
| | Career Choice | 1 | 2018 | 177 | 0.030 |
Why?
| | Inventions | 1 | 2016 | 18 | 0.030 |
Why?
| | Hemoperitoneum | 1 | 2016 | 11 | 0.030 |
Why?
| | History, 20th Century | 1 | 2017 | 265 | 0.030 |
Why?
| | Device Removal | 1 | 2017 | 126 | 0.030 |
Why?
| | Portography | 1 | 2016 | 11 | 0.030 |
Why?
| | Portal Pressure | 1 | 2016 | 4 | 0.030 |
Why?
| | Pregnancy, Ectopic | 1 | 2016 | 52 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 117 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2016 | 70 | 0.030 |
Why?
| | Operative Time | 1 | 2016 | 106 | 0.030 |
Why?
| | Radiation Exposure | 1 | 2016 | 40 | 0.030 |
Why?
| | Models, Organizational | 1 | 2016 | 140 | 0.030 |
Why?
| | Fluoroscopy | 1 | 2016 | 138 | 0.030 |
Why?
| | Adult | 5 | 2016 | 30543 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2016 | 135 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 130 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2016 | 12513 | 0.030 |
Why?
| | Program Development | 1 | 2017 | 342 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 484 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 2016 | 218 | 0.030 |
Why?
| | Time Factors | 2 | 2016 | 6124 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2016 | 228 | 0.030 |
Why?
| | Contrast Media | 1 | 2016 | 343 | 0.030 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 47 | 0.030 |
Why?
| | Middle Aged | 4 | 2016 | 26746 | 0.030 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 56 | 0.030 |
Why?
| | Ultrasonography | 1 | 2016 | 629 | 0.030 |
Why?
| | Adolescent | 3 | 2016 | 17808 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 822 | 0.030 |
Why?
| | Laparoscopy | 1 | 2016 | 388 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 494 | 0.020 |
Why?
| | Genes, Neoplasm | 1 | 2011 | 20 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1773 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2011 | 63 | 0.020 |
Why?
| | Reoperation | 1 | 2013 | 514 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 622 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2011 | 49 | 0.020 |
Why?
| | ras Proteins | 1 | 2012 | 138 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 158 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 815 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 229 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1690 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 169 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 8626 | 0.020 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 179 | 0.020 |
Why?
| | Kidney | 1 | 2016 | 1184 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 797 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 528 | 0.020 |
Why?
| | Genome, Human | 1 | 2011 | 351 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 743 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1468 | 0.020 |
Why?
| | Nephrectomy | 1 | 2010 | 149 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 560 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 728 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 263 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 258 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 610 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1218 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 2762 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1435 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1378 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2639 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 5035 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 2725 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 5525 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 863 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 6346 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4086 | 0.010 |
Why?
| | Infant | 1 | 2016 | 7935 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 9079 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3334 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1361 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3349 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3031 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1895 | 0.010 |
Why?
| | Child | 1 | 2016 | 18352 | 0.010 |
Why?
|
|
Kondo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|